Sutureless versus conventional bioprostheses for aortic valve replacement in severe symptomatic aortic valve stenosis
- PMID: 33478837
- DOI: 10.1016/j.jtcvs.2020.11.162
Sutureless versus conventional bioprostheses for aortic valve replacement in severe symptomatic aortic valve stenosis
Abstract
Objective: Sutureless aortic valves are a novel option for aortic valve replacement. We sought to demonstrate noninferiority of sutureless versus standard bioprostheses in severe symptomatic aortic stenosis.
Methods: The Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement is a prospective, randomized, adaptive, open-label trial. Patients were randomized (March 2016 to September 2018) to aortic valve replacement with a sutureless or stented valve using conventional or minimally invasive approach. Primary outcome was freedom from major adverse cerebral and cardiovascular events (composite of all-cause death, myocardial infarction, stroke, or valve reintervention) at 1 year.
Results: At 47 centers (12 countries), 910 patients were randomized to sutureless (n = 453) or conventional stented (n = 457) valves; mean ages were 75.4 ± 5.6 and 75.0 ± 6.1 years, and 50.1% and 44.9% were female, respectively. Mean ± standard deviation Society of Thoracic Surgeons scores were 2.4 ± 1.7 and 2.1 ± 1.3, and a ministernotomy approach was used in 50.4% and 47.3%, respectively. Concomitant procedures were performed with similar rates in both groups. Noninferiority was demonstrated for major adverse cerebral and cardiovascular events at 1 year, whereas aortic valve hemodynamics improved equally in both groups. Use of sutureless valves significantly reduced surgical times (mean extracorporeal circulation times: 71.0 ± 34.1 minutes vs 87.8 ± 33.9 minutes; mean crossclamp times: 48.5 ± 24.7 vs 65.2 ± 23.6; both P < .0001), but resulted in a higher rate of pacemaker implantation (11.1% vs 3.6% at 1 year). Incidences of perivalvular and central leak were similar.
Conclusions: Sutureless valves were noninferior to stented valves with respect to major adverse cerebral and cardiovascular events at 1 year in patients undergoing aortic valve replacement (alone or with coronary artery bypass grafting). This suggests that sutureless valves should be considered as part of a comprehensive valve program.
Keywords: aortic valve replacement; randomized controlled trial; sutureless.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Comment in
-
Commentary: Perceval sutureless valve-one more seat at the round table of short-term follow-up.J Thorac Cardiovasc Surg. 2021 Mar;161(3):934. doi: 10.1016/j.jtcvs.2020.11.133. Epub 2020 Dec 3. J Thorac Cardiovasc Surg. 2021. PMID: 33422312 No abstract available.
-
Commentary: The confirmation.J Thorac Cardiovasc Surg. 2021 Mar;161(3):935-936. doi: 10.1016/j.jtcvs.2020.12.018. Epub 2020 Dec 13. J Thorac Cardiovasc Surg. 2021. PMID: 33431205 No abstract available.
-
Commentary: Sutureless bioprosthesis: Simpler than conventional bioprostheses.J Thorac Cardiovasc Surg. 2021 Mar;161(3):933. doi: 10.1016/j.jtcvs.2020.12.010. Epub 2020 Dec 9. J Thorac Cardiovasc Surg. 2021. PMID: 33454104 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
